
==== Front
CNS Neurosci Ther
CNS Neurosci Ther
10.1111/(ISSN)1755-5949
CNS
CNS Neuroscience & Therapeutics
1755-5930
1755-5949
John Wiley and Sons Inc. Hoboken

38465461
10.1111/cns.14667
CNS14667
Retraction
Retraction
Retraction: Abdallah MS, Mosalam EM, Hassan A, et al. Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial. CNS Neurosci. Ther. 2023;29:354–364 (https://doi.org/10.1111/cns.14010)
11 3 2024
3 2024
11 3 2024
30 3 10.1002/cns.v30.3 e14667© 2024 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

10.1111/cns.13731 Retraction: Abdallah MS, Ramadan AN, Omara‐Reda H, et al. Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neurosci. Ther. 2021;27:1540–1548 (https://doi.org/10.1111/cns.13731)

The above article, published online on September 21, 2021 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd.

Following publication, multiple concerns were raised by a third party about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.

source-schema-version-number2.0
cover-dateMarch 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:11.03.2024
==== Body
pmc Retraction: Abdallah MS, Ramadan AN, Omara‐Reda H, et al. Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder. CNS Neurosci. Ther. 2021;27:1540–1548 (https://doi.org/10.1111/cns.13731)

The above article, published online on September 21, 2021 in Wiley Online Library (wileyonlinelibrary.com) has been retracted by agreement between the journal's Editor‐in‐Chief, Xiaoming Hu, and John Wiley and Sons Ltd.

Following publication, multiple concerns were raised by a third party about the integrity of the clinical trial. An investigation revealed significant issues regarding the reliability of the reported data. As a result, the Editor‐in‐Chief no longer has confidence in the validity of the results presented in this article.
